Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Everist Genomics Announces Worldwide Availability of OncoDefenderâ„¢-CRC

March 28, 2011 By Bio-Medicine.Org

ANN ARBOR, Mich., March 28, 2011 /PRNewswire/ — Everist
Genomics today announced the worldwide commercial availability of
its OncoDefender-CRC colorectal cancer assay, the first and only
molecular prognostic test capable of accurately predicting the risk
of recurrence of cancer in patients previously treated with
surgical resection of a Stage I/II colon cancer tumor or Stage I
rectal cancer tumor.  The OncoDefender-CRC test examines
expression levels of a panel of genes extracted from formalin-fixed
paraffin-embedded cancer tissue taken at the time of surgery, and
uses a proprietary computer-generated decision rule to identify
patients who are at risk of recurrence.  Patients identified
by OncoDefender-CRC at high-risk of cancer recurrence may benefit
from adjuvant therapy or other more aggressive treatment options,
as reported at the 2011 American Society of Clinical Oncology
(ASCO) meeting. (1)

(Logo:
https://photos.prnewswire.com/prnh/20110110/NY26865LOGO)

“We are pleased to deliver a new molecular prognostic test
capable of assessing recurrence risk in early stage colorectal
cancer patients, including the neglected stage I subset, where the
lack of positive predictive prognostics presents a significant
unmet need,” said Prasad Sunkara, Ph.D., Chief Executive Officer of
Everist Genomics.  OncoDefender-CRC was developed through
extensive clinical research and assay validation studies involving
over 500 patients from around the world.  “OncoDefender-CRC
will help physicians make patient management decisions that
promptly and reliably direct the most effective treatment to those
individual Stage I/II colon cancer and Stage I rectal cancer
patients at high risk for tumor recurrence, while minimizing the
exposure of low-risk patients to unnecessary, costly, and
potentially toxic chemotherapy and/or radiotherapy.”

Traditional standards for assessing a patient’s risk of cancer
recurrence have depended solely on the cancer’s a

‘/>”/>

SOURCE

Related Articles Read More >

UMN artificial blood vessel clinical trial
Minnesota researchers awarded $3.7M grant for artificial, bioengineered blood vessel clinical trial
CeQur Simplicity
CeQur is launching a discreet, convenient ‘wearable insulin pen’
Blackrock's Utah array is a miniature array of electrodes for sensing brain signals
Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
Engineer inspecting artificial hip joint parts in quality control department in orthopaedic factory
Deburring and finishing for beautiful, functional medical devices

DeviceTalks Weekly.

August 5, 2022
DTW Medtronic's Greg Smith lays out supply chain strategies
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech